Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategic review
Biotech
Blocked by FDA, Passage cuts headcount by 75%
The layoffs are part of a strategic review sparked by the FDA's refusal to allow Passage's gene therapy trial to be single-arm.
Darren Incorvaia
May 4, 2026 1:33pm
CNS Pharma wipes glioblastoma pipeline clean in strategic pivot
Mar 11, 2026 10:30am
MindMaze seeks 'strategic alternatives,' eyes US expansion
Mar 3, 2026 9:25am
Charles River sells CDMO and discovery assets in strategic pivot
Feb 25, 2026 1:54pm
Charles River's incoming CEO talks R&D processes, reorg goals
Jan 28, 2026 12:58pm
Tempest strikes all-stock deal for Factor’s CAR-T pipeline, CEO
Nov 19, 2025 12:22pm
